BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT ST. PAUL, Minn., July 24 /PRNewswire/ -- Bioplasty, Inc.
(NASDAQ-NMS: BIOP) announced today that it has settled the lawsuit brought by Collagen Corporation (NASDAQ: CGEN) alleging Bioplasty's Bioplastique(TM) and Macroplastique(TM) Macro Implant products infringed a Collagen U.S. patent. Pursuant to the terms of the settlement agreement and in return for a royalty, Bioplasty has maintained its right to manufacture, sell and market Bioplastique and Macroplastique throughout all domestic and foreign markets. Bioplastique is an injectable implant device designed to correct soft tissue defects in cosmetic and reconstructive plastic surgery applications, and Macroplastique is a similar product used to treat certain forms of urinary incontinence.
Bioplasty, Inc. has more than 20 years of experience in the development, manufacturing and marketing of plastic surgery products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol "BIOP." -0- 7/24/92 /CONTACT: Timothy P. Lawin or Donald A. Major, 612-636-4112/ (BIOP) CO: Bioplasty, Inc. ST: Minnesota IN: MTC SU:
AL -- MN003 -- 3029 07/24/92 12:24 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 24, 1992|
|Previous Article:||NATURAL EARTH TECHNOLOGIES ANNOUNCES 'GARDEN THUNDER LINE' TEST RESULTS|
|Next Article:||PORT AUTHORITY TO GIVE PRESS TOUR OF VETPORT AT JFK AIRPORT|